Shilpa Medicare is pleased to announce the receipt of Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at API manufacturing site located at Raichur, Karnataka, India during the period between '03rd February and 07th February 2020'. USFDA has determined that the inspection classification of this facility is "NO ACTION INDICATED" ("NAI").